NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting

July 21, 2017

CARY, N.C. (July 21, 2017) — Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.’s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA). NERLYNX is indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

“We are pleased to be part of the distribution network for NERLYNX, as this promising agent provides oncologists a new treatment option for HER2-positive patients who remain at significant risk for disease recurrence after targeted therapy,” said Brandon Tom, vice president, Biopharma Services, McKesson Specialty Health. “As prospects are poor for HER2-positive patients whose disease returns, any therapy that reduces the risk of recurrence is a welcome addition to the treatment options.”

The most common adverse reactions associated with NERLYNX (≥5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight decrease and urinary tract infection.

Biologics’ oncology specialty pharmacy is recognized across the industry for its high-touch care model that supports patients with a multidisciplinary care team throughout the patient’s cancer journey. Working together on behalf of the patient, the care team develops an individualized care plan that addresses the unique clinical, financial and emotional needs of each patient, streamlining communication back to the treating provider while empowering high-quality care. Each team includes a pharmacist with in-depth knowledge of oncology pharmaceuticals, an experienced oncology nurse who understands the unique clinical and psychosocial needs of cancer patients, and a financial counselor who is familiar with various financial assistance programs and organizations available to help cancer patients. The goal of this unique support system and patient-centric care model is to drive optimal outcomes and help ensure the best possible patient experience.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

Please click for Full Prescribing Information, including Patient Information. For additional IMPORTANT SAFETY INFORMATION, visit

About Biologics

Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.

Biologics is part of McKesson Specialty Health, a division of McKesson Corporation empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit and

Public Relations Contact